Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 57Biopsy 44pembrolizumab 38Carboplatin 32Nivolumab 29Cyclophosphamide 27Radiotherapy 26Radiation 25Paclitaxel 24Cisplatin 24olaparib 21Etoposide 19Doxorubicin 18durvalumab 17Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17Bevacizumab 17X-Rays 16Vincristine 16Prednisone 16Immunoglobulin G 16Disulfides 16Cytarabine 15Platinum 14Leucovorin 14Docetaxel 14Pemetrexed 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × polatuzumab vedotin × 30 days × Clear all
NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Completed
42 enrolled 10 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡